Blood Product Supply

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT07490314
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Document delays and frequencies of inadequate blood products for emergent cases — OTHER
    The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

Study Details

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Key Dates

First listed
Mar 24, 2026
Start date
Mar 1, 2020
Status verified
Feb 2026
Primary completion
Mar 21, 2021
Completion
Jun 25, 2025

Study Design

Enrollment
100 participants (actual)

Arms

  • Arm: future policies on use of blood products from COVID-19-positive donors
    Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics.

Primary Outcome Measure

Time frame [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Methodist Dallas Medical Center- Clinical Research InstituteDallasTexas75203-

Find similar trials in Dallas, TX

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Methodist Dallas Medical Center- Clinical Research Institute· Dallas, TX

Related Studies